BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 11696596)

  • 1. Identification of cyclin B1 as a shared human epithelial tumor-associated antigen recognized by T cells.
    Kao H; Marto JA; Hoffmann TK; Shabanowitz J; Finkelstein SD; Whiteside TL; Hunt DF; Finn OJ
    J Exp Med; 2001 Nov; 194(9):1313-23. PubMed ID: 11696596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of Hydroxysteroid (17β) dehydrogenase type 12 (HSD17B12) as a CD8+ T-cell-defined human tumor antigen of human carcinomas.
    Visus C; Ito D; Dhir R; Szczepanski MJ; Chang YJ; Latimer JJ; Grant SG; DeLeo AB
    Cancer Immunol Immunother; 2011 Jul; 60(7):919-29. PubMed ID: 21409596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cross-priming of cyclin B1, MUC-1 and survivin-specific CD8+ T cells by dendritic cells loaded with killed allogeneic breast cancer cells.
    Saito H; Dubsky P; Dantin C; Finn OJ; Banchereau J; Palucka AK
    Breast Cancer Res; 2006; 8(6):R65. PubMed ID: 17129372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD8 T-cell responses against cyclin B1 in breast cancer patients with tumors overexpressing p53.
    Sørensen RB; Andersen RS; Svane IM; Engell-Noerregaard L; Hadrup SR; Balslev E; Andersen MH; thor Straten P
    Clin Cancer Res; 2009 Mar; 15(5):1543-9. PubMed ID: 19223507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of human aldehyde dehydrogenase 1 family member A1 as a novel CD8+ T-cell-defined tumor antigen in squamous cell carcinoma of the head and neck.
    Visus C; Ito D; Amoscato A; Maciejewska-Franczak M; Abdelsalem A; Dhir R; Shin DM; Donnenberg VS; Whiteside TL; DeLeo AB
    Cancer Res; 2007 Nov; 67(21):10538-45. PubMed ID: 17974998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunological characterization of missense mutations occurring within cytotoxic T cell-defined p53 epitopes in HLA-A*0201+ squamous cell carcinomas of the head and neck.
    Ito D; Visus C; Hoffmann TK; Balz V; Bier H; Appella E; Whiteside TL; Ferris RL; DeLeo AB
    Int J Cancer; 2007 Jun; 120(12):2618-24. PubMed ID: 17294448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro generated cytolytic T lymphocytes reactive against head and neck cancer recognize multiple epitopes presented by HLA-A2, including peptides derived from the p53 and MDM-2 proteins.
    Asai T; Storkus WJ; Mueller-Berghaus J; Knapp W; DeLeo AB; Chikamatsu K; Whiteside TL
    Cancer Immun; 2002 Apr; 2():3. PubMed ID: 12747748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune recognition of cyclin B1 as a tumor antigen is a result of its overexpression in human tumors that is caused by non-functional p53.
    Yu M; Zhan Q; Finn OJ
    Mol Immunol; 2002 May; 38(12-13):981-7. PubMed ID: 12009577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of human melanoma peptides recognized by class I restricted tumor infiltrating T lymphocytes.
    Storkus WJ; Zeh HJ; Maeurer MJ; Salter RD; Lotze MT
    J Immunol; 1993 Oct; 151(7):3719-27. PubMed ID: 7690811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human CD8 and CD4 T cell epitopes of epithelial cancer antigens.
    Sato N; Nabeta Y; Kondo H; Sahara H; Hirohashi Y; Kashiwagi K; Kanaseki T; Sato Y; Rong S; Hirai I; Kamiguchi K; Tamura Y; Matsuura A; Takahashi S; Torigoe T; Ikeda H
    Cancer Chemother Pharmacol; 2000; 46 Suppl():S86-90. PubMed ID: 10950155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recognition of breast cancer-associated peptides by tumor-reactive, HLA-class I restricted allogeneic cytotoxic T lymphocytes.
    Nguyen T; Naziruddin B; Dintzis S; Doherty GM; Mohanakumar T
    Int J Cancer; 1999 May; 81(4):607-15. PubMed ID: 10225452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequencies of tetramer+ T cells specific for the wild-type sequence p53(264-272) peptide in the circulation of patients with head and neck cancer.
    Hoffmann TK; Donnenberg AD; Finkelstein SD; Donnenberg VS; Friebe-Hoffmann U; Myers EN; Appella E; DeLeo AB; Whiteside TL
    Cancer Res; 2002 Jun; 62(12):3521-9. PubMed ID: 12067999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection and quantification of blood-derived CD8+ T lymphocytes secreting tumor necrosis factor alpha in response to HLA-A2.1-binding melanoma and viral peptide antigens.
    Herr W; Schneider J; Lohse AW; Meyer zum Büschenfelde KH; Wölfel T
    J Immunol Methods; 1996 May; 191(2):131-42. PubMed ID: 8666832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a cyclin B1-derived CTL epitope eliciting spontaneous responses in both cancer patients and healthy donors.
    Andersen RS; Sørensen RB; Ritter C; Svane IM; Becker JC; thor Straten P; Andersen MH
    Cancer Immunol Immunother; 2011 Feb; 60(2):227-34. PubMed ID: 20981424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes.
    Brossart P; Stuhler G; Flad T; Stevanovic S; Rammensee HG; Kanz L; Brugger W
    Cancer Res; 1998 Feb; 58(4):732-6. PubMed ID: 9485028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The tumor antigens RHAMM and G250/CAIX are expressed in head and neck squamous cell carcinomas and elicit specific CD8+ T cell responses.
    Schmitt A; Barth TF; Beyer E; Borchert F; Rojewski M; Chen J; Guillaume P; Gronau S; Greiner J; Möller P; Riechelmann H; Schmitt M
    Int J Oncol; 2009 Mar; 34(3):629-39. PubMed ID: 19212667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High frequency of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long survival.
    Karanikas V; Colau D; Baurain JF; Chiari R; Thonnard J; Gutierrez-Roelens I; Goffinet C; Van Schaftingen EV; Weynants P; Boon T; Coulie PG
    Cancer Res; 2001 May; 61(9):3718-24. PubMed ID: 11325844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of naturally processed human ovarian peptides recognized by tumor-associated CD8+ cytotoxic T lymphocytes.
    Fisk B; Anderson BW; Gravitt KR; O'Brian CA; Kudelka AP; Murray JL; Wharton JT; Ioannides CG
    Cancer Res; 1997 Jan; 57(1):87-93. PubMed ID: 8988046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A wild-type sequence p53 peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize squamous cell carcinomas of the head and neck.
    Eura M; Chikamatsu K; Katsura F; Obata A; Sobao Y; Takiguchi M; Song Y; Appella E; Whiteside TL; DeLeo AB
    Clin Cancer Res; 2000 Mar; 6(3):979-86. PubMed ID: 10741724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and characterization of HLA-class-I-restricted T-cell epitopes in the putative tumor-associated antigens P21-activated serin kinase 2 (PAK2) and cyclin-dependent kinase inhibitor 1A (CDKN1A).
    Li G; Hundemer M; Wolfrum S; Ho AD; Goldschmidt H; Witzens-Harig M
    Ann Hematol; 2006 Sep; 85(9):583-90. PubMed ID: 16718496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.